These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 22989856)

  • 21. Access to orphan drugs in Europe: current and future issues.
    Michel M; Toumi M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What is wrong with orphan drug policies? Suggestions for ways forward.
    Kanavos P; Nicod E
    Value Health; 2012 Dec; 15(8):1182-4. PubMed ID: 23244822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cross-national comparison of orphan drug policies: implications for the U.S. Orphan Drug Act.
    Thamer M; Brennan N; Semansky R
    J Health Polit Policy Law; 1998 Apr; 23(2):265-90. PubMed ID: 9565894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Partnerships and communities in English drug policy: the challenge of deprivation.
    Macgregor S; Thickett A
    Int J Drug Policy; 2011 Nov; 22(6):478-90. PubMed ID: 21890338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating mental health care and policy in Spain.
    Salvador-Carulla L; Costa-Font J; Cabases J; McDaid D; Alonso J
    J Ment Health Policy Econ; 2010 Jun; 13(2):73-86. PubMed ID: 20919594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME
    Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding orphan drug regulations: an EU and U.S. comparative analysis.
    Grienenberger A
    J Biolaw Bus; 2004; 7(3):58-61. PubMed ID: 15460604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What is wrong with orphan drug policies?
    Côté A; Keating B
    Value Health; 2012 Dec; 15(8):1185-91. PubMed ID: 23244823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
    Nicod E
    Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defining European preparedness and research needs regarding emerging infectious animal diseases: results from a Delphi expert consultation.
    Wentholt MT; Cardoen S; Imberechts H; Van Huffel X; Ooms BW; Frewer LJ
    Prev Vet Med; 2012 Feb; 103(2-3):81-92. PubMed ID: 22000288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Orphan drugs. EU regulations.
    Mariz S; Llinares J; Westermark K
    BMJ; 2011 Jan; 342():d136. PubMed ID: 21224321
    [No Abstract]   [Full Text] [Related]  

  • 33. Review of 11 national policies for rare diseases in the context of key patient needs.
    Dharssi S; Wong-Rieger D; Harold M; Terry S
    Orphanet J Rare Dis; 2017 Mar; 12(1):63. PubMed ID: 28359278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Is it possible (and desirable) to administer a standard for an effective health policy for the European Union?].
    Bruch M
    Bull Soc Sci Med Grand Duche Luxemb; 1997; 134(2):5-10. PubMed ID: 9534267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [EURO-Medicines: a European program for bringing into agreement public health policies on drugs].
    Calamo-Specchia F; Bucci R; Folino-Gallo P
    Ann Ig; 1998; 10(5-6):405-12. PubMed ID: 10052204
    [No Abstract]   [Full Text] [Related]  

  • 36. Market uptake of orphan drugs--a European analysis.
    Picavet E; Annemans L; Cleemput I; Cassiman D; Simoens S
    J Clin Pharm Ther; 2012 Dec; 37(6):664-7. PubMed ID: 22731105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Orphan Drugs: Underrated Opportunities for The Developers in Europe].
    Tillet Y; Maillols-Perroy AC
    Therapie; 2015; 70(4):351-7. PubMed ID: 25997721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peer, professional, and public: an analysis of the drugs policy advocacy community in Europe.
    O'Gorman A; Quigley E; Zobel F; Moore K
    Int J Drug Policy; 2014 Sep; 25(5):1001-8. PubMed ID: 24974366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What should the government do regarding health policy-making to develop community health care in Shanghai?
    Yu Y; Sun X; Zhuang Y; Dong X; Liu H; Jiang P; Yu Z; Zhang Y
    Int J Health Plann Manage; 2011; 26(4):379-435. PubMed ID: 22213259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multi-level governance: The way forward for European illicit drug policy?
    Chatwin C
    Int J Drug Policy; 2007 Dec; 18(6):494-502. PubMed ID: 18061875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.